Report from the NEI/FDA ophthalmic clinical trial design and endpoints symposium

被引：187
|
作者：
Csaky, Karl G. [1 ]
Richman, Elaine A. [2 ]
Ferris, Frederick L., III [3 ]
机构：
[1] Duke Univ, Med Ctr, Ophthalm Unit, DCRI, Durham, NC 27710 USA
[2] Richman Associates LLC, Baltimore, MD USA
[3] NEI, NIH, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2008年 / 49卷 / 02期
关键词：
D O I：
10.1167/iovs.07-1132
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：479 / 489
页数：11
相关论文
共 50 条
  • [41] An international, multicenter renal allograft rejection database to define endpoints for clinical trial design.
    不详
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A3269 - A3269
  • [42] Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
    Slovin, Susan F.
    IMMUNOTARGETS AND THERAPY, 2014, 3 : 1 - 8
  • [43] Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design
    Abreu, Maria T.
    Sandborn, William J.
    GASTROENTEROLOGY, 2020, 159 (06) : 2013 - 2018.e7
  • [44] Clinical trial design and scoring of radionuclide therapy endpoints: Normal organ toxicity and tumor response
    Meredith, R
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2002, 17 (01) : 83 - 99
  • [45] Pediatric Analgesic Clinical Trial Designs, Measures, and Extrapolation: Report of an FDA Scientific Workshop
    Berde, Charles B.
    Walco, Gary A.
    Krane, Elliot J.
    Anand, K. J. S.
    Aranda, Jacob V.
    Craig, Kenneth D.
    Dampier, Carlton D.
    Finkel, Julia C.
    Grabois, Martin
    Johnston, Celeste
    Lantos, John
    Lebel, Alyssa
    Maxwell, Lynne G.
    McGrath, Patrick
    Oberlander, Timothy F.
    Schanberg, Laura E.
    Stevens, Bonnie
    Taddio, Anna
    von Baeyer, Carl L.
    Yaster, Myron
    Zempsky, William T.
    PEDIATRICS, 2012, 129 (02) : 354 - 364
  • [46] TFOS DEWS II Clinical Trial Design Report
    Novack, Gary D.
    Asbell, Penny
    Barabino, Stefano
    Bergamini, Michael V. W.
    Ciolino, Joseph B.
    Foulks, Gary N.
    Goldstein, Michael
    Lemp, Michael A.
    Schrader, Stefan
    Woods, Craig
    Stapleton, Fiona
    OCULAR SURFACE, 2017, 15 (03): : 629 - 649
  • [47] Is the FDA too conservative or too aggressive?: A Bayesian decision analysis of clinical trial design
    Isakov, Leah
    Lo, Andrew W.
    Montazerhodjat, Vahid
    JOURNAL OF ECONOMETRICS, 2019, 211 (01) : 117 - 136
  • [48] Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal
    Mark A. Talamini
    Surgical Endoscopy, 2013, 27 : 701 - 701
  • [49] The Conflict of Safety Versus Access to New Therapies: The FDA, Clinical Trial Design, and Neuromodulation
    Levy, Robert M.
    NEUROMODULATION, 2012, 15 (01): : 1 - 4
  • [50] Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal
    Lerner, Herbert
    Whang, Joyce
    Nipper, Rebecca
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2013, 27 (03): : 702 - 707
12345